uploads/2019/02/3-7.jpg

What Are Analysts Recommending for Curaleaf Holdings?

By

Updated

Analysts’ recommendations

Of the three analysts that cover Curaleaf Holdings (CURLF), two are favoring a “strong buy,” and one is favoring a “buy.” On average, analysts have set a 12-month price target of 16.67 Canadian dollars, which represents an upside potential of 83.8% from its February 5 closing price of 9.07 Canadian dollars. On December 18, Canaccord Genuity had initiated a speculative “buy” rating for Curaleaf with a price target of 9.0 Canadian dollars.

Article continues below advertisement
  • Of the six analysts that follow Cronos Group (CRON), four analysts have given the stock a “buy” rating, while two are favoring a “hold.” On average, analysts have set a 12-month price target of 20.0 Canadian dollars, which represents a fall of 30.3% from its stock price of 28.70 Canadian dollars.
  • Of the six analysts that follow MedMen Enterprises (MMNFF), two analysts have given the stock a “strong buy” rating, while four analysts are favoring a “buy” rating. On average, analysts have set a price target of 8.18 Canadian dollars, which represents an upside potential of 95.6% from 4.18 Canadian dollars.
  • Of the six analysts covering Tilray (TLRY), three analysts have given the stock a “strong buy” rating, while three analysts have given the stock a “hold” rating. On average, analysts have set a 12-month price target of $131.25, which represents an upside potential of 57.6% from $83.27.

Valuation multiple

As of February 5, 2019, Curaleaf was trading at a forward PE (price-to-earnings) multiple of 53.8x. On the same day, peers Planet 13 Holdings (PLNHF), HEXO (HEXO), and Cronos Group were trading at a forward PE multiple of 15.6x, 86.9x, and 292.8x, respectively.

Advertisement

More From Market Realist